US · ELTX · BIOTECHNOLOGY
Elicio Therapeutics, Inc. (ELTX) intrinsic value and stock valuation
$1.45as of 2026-11-21 · Mkt cap 60.82M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Elicio Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values ELTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ELTX’s statements →
Elicio Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $28.3M |
| Operating income | -$-37.71M | -$-44.99M | -$-35.74M | -$-23.73M | -$-39.31M |
| Net income | -$-39.57M | -$-51.9M | -$-35.2M | -$-28.21M | -$-26.4M |
| EPSd | -$-2.58M | -$-4.25M | -$-6.96M | -$-9.1M | -$-8.25M |
| Operating cash flow | -$-36.95M | -$-37.07M | -$-32.69M | -$-22.18M | -$-23.94M |
| Capital expenditure | -$-20K | -$-90K | -$-70K | -$-650K | -$-530K |
| Free cash flow | -$-36.97M | -$-37.16M | -$-32.76M | -$-22.83M | -$-24.46M |
| Total assets | $25.9M | $28.2M | $27.2M | $22.7M | $96.5M |
| Total debt | $14.5M | $26M | $6.92M | $7.48M | $4.66M |
| Net debt | -$-4.05M | $8.42M | -$-5.98M | -$-320K | -$-84.09M |
| Total equity | $1.64M | -$-11.31M | $11.4M | $8.91M | $81.5M |
| Cash and short-term investments | $18.6M | $17.6M | $12.9M | $7.8M | $88.8M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $28.3M |
| Cost of revenue | $1.13M | $1.18M | $1.17M | $1.06M | $1.23M |
| Gross profit | -$-1.13M | -$-1.18M | -$-1.17M | -$-1.06M | $27.1M |
| Research and development expenses | $24.9M | $33.7M | $22.7M | $17.1M | $48.6M |
| Selling, general and administrative expenses | $12.8M | $11.3M | $11.9M | $5.63M | $17.8M |
| Other expenses | -$-1.13M | -$-1.18M | $0.00 | $0.00 | $0.00 |
| Operating expenses | $36.6M | $43.8M | $34.6M | $22.7M | $66.4M |
| Cost and expenses | $37.7M | $45M | $35.7M | $23.7M | $67.6M |
| Interest income | $780K | $780K | $370K | $60K | $0.00 |
| Interest expense | $1.13M | $460K | $1.06M | $3.6M | $880K |
| Depreciation and amortization | $1.13M | $1.18M | $1.17M | $1.06M | $800K |
| Ebitda | -$-37.31M | -$-50.27M | -$-32.97M | -$-23.55M | -$-51.92M |
| Operating income | -$-37.71M | -$-44.99M | -$-35.74M | -$-23.73M | -$-39.31M |
| Total other income/expenses, net | -$-1.86M | -$-6.91M | $550K | -$-4.47M | -$-15.27M |
| Income before tax | -$-39.57M | -$-51.9M | -$-35.2M | -$-28.21M | -$-54.57M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-39.57M | -$-51.9M | -$-35.2M | -$-28.21M | -$-26.4M |
| Weighted average shares outstanding | $15.3M | $12.2M | $5.06M | $3.1M | $3.2M |
| Weighted average diluted shares outstanding | $15.3M | $12.2M | $5.06M | $3.1M | $3.2M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $18.6M | $17.6M | $12.9M | $7.8M | $88.8M |
| Net receivables | $0.00 | $0.00 | $0.00 | $0.00 | $810K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $19.3M | $20.7M | $16.4M | $10.7M | $91.3M |
| Property, plant and equipment, net | $5.08M | $6.19M | $7.28M | $8.5M | $4.44M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $700K | $0.00 | $620K | $720K |
| Total non-current assets | $6.55M | $7.49M | $10.8M | $12M | $5.27M |
| Total assets | $25.9M | $28.2M | $27.2M | $22.7M | $96.5M |
| Accounts payable | $670K | $1.04M | $4.37M | $2.81M | $4.71M |
| Short-term debt | $1.01M | $900K | $910K | $690K | $950K |
| Deferred revenue | $0.00 | $1.17M | $0.00 | $1.44M | $2.3M |
| Total current liabilities | $8.11M | $11.5M | $9.76M | $6.87M | $11.3M |
| Long-term debt | $13.5M | $25.1M | $6.01M | $6.79M | $3.71M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $16.1M | $28M | $6.02M | $6.88M | $3.71M |
| Capital lease obligations | $5.11M | $5.11M | $6.92M | $6.79M | $3.71M |
| Total liabilities | $24.2M | $39.5M | $15.8M | $13.8M | $15M |
| Common stock | $180K | $110K | $100K | $0.00 | $300K |
| Retained earnings | -$-233.67M | -$-194.1M | -$-142.2M | -$-107.01M | -$-215.13M |
| Accumulated other comprehensive income (loss) | -$-130K | -$-170K | -$-200K | $0.00 | -$-100K |
| Total equity | $1.64M | -$-11.31M | $11.4M | $8.91M | $81.5M |
| Total investments | $0.00 | $700K | $0.00 | $620K | $720K |
| Total debt | $14.5M | $26M | $6.92M | $7.48M | $4.66M |
| Net debt | -$-4.05M | $8.42M | -$-5.98M | -$-320K | -$-84.09M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-39.57M | -$-51.9M | -$-35.2M | -$-28.21M | -$-26.4M |
| Depreciation and amortization | $1.13M | $1.18M | $1.17M | $1.06M | $250K |
| Stock-based compensation | $2.7M | $1.45M | $1.18M | $580K | $620K |
| Change in working capital | -$-3.44M | $3.96M | -$-60K | -$-150K | $870K |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-370K | -$-3.33M | $20K | $1.12M | $30K |
| Net cash provided by operating activities | -$-36.95M | -$-37.07M | -$-32.69M | -$-22.18M | -$-23.94M |
| Investments in property, plant and equipment | -$-20K | -$-90K | -$-70K | -$-650K | -$-530K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-20K | -$-80K | -$-30K | -$-650K | -$-530K |
| Common stock issued | $26.8M | $5.63M | $7M | $80K | $100K |
| Common stock repurchased | $0.00 | $0.00 | -$-150K | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $36.7M | $42.3M | $38.6M | $21.2M | $19.4M |
| Net change in cash | -$-230K | $5.19M | $5.89M | -$-80.96M | -$-5.07M |
| Cash at end of period | $19.3M | $19.5M | $14.3M | $7.8M | $10M |
| Operating cash flow | -$-36.95M | -$-37.07M | -$-32.69M | -$-22.18M | -$-23.94M |
| Capital expenditure | -$-20K | -$-90K | -$-70K | -$-650K | -$-530K |
| Free cash flow | -$-36.97M | -$-37.16M | -$-32.76M | -$-22.83M | -$-24.46M |
Line items
Line items
Line items
About Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
- CEO
- Robert T. Connelly
- Employees
- 33
- Beta
- 1.78
Explore
Frequently asked questions
What is the intrinsic value of Elicio Therapeutics, Inc. (ELTX)?
InvestorsCraft does not currently publish an intrinsic value for ELTX. How the IC value is calculated.
Is ELTX undervalued?
InvestorsCraft does not publish an undervaluation signal for ELTX at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.